We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Skin problems and EGFR-tyrosine kinase inhibitor.
- Authors
Toshiyuki Kozuki
- Abstract
Epidermal growth factor receptor inhibition is a good target for the treatment of lung, colon, pancreatic and head and neck cancers. Epidermal growth factor receptor-tyrosine kinase inhibitor was first approved for the treatment of advanced lung cancer in 2002. Epidermal growth factor receptortyrosine kinase inhibitor plays an essential role in the treatment of cancer, especially for patients harbouring epidermal growth factor receptor activating mutation. Hence, skin toxicity is the most concerning issue for the epidermal growth factor receptor-tyrosine kinase inhibitor treatment. Skin toxicity is bothersome and sometimes affects the quality of life and treatment compliance. Thus, it is important for physicians to understand the background and how to manage epidermal growth factor receptor-tyrosine kinase inhibitor-associated skin toxicity. Here, the author reviewed the mechanism and upfront preventive and reactive treatments for epidermal growth factor receptor inhibitor-associated skin toxicities.
- Publication
Japanese Journal of Clinical Oncology, 2016, Vol 46, Issue 4, p291
- ISSN
0368-2811
- Publication type
Article
- DOI
10.1093/jjco/hyv207